Clinical trial
A Phase 2, Double-blind, Active-controlled, Dose-titrating Efficacy and Safety Study of Firibastat Compared to Ramipril Administered Orally, Twice Daily, Over 12 Weeks to Prevent Left Ventricular Dysfunction After Acute MI
NCT03715998 is registered in ClinicalTrials.gov with Quantum Genomics SA as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2, Double-blind, Active-controlled, Dose-titrating Efficacy and Safety Study of Firibastat Compared to Ramipril Administered Orally, Twice Daily, Over 12 Weeks to Prevent Left Ventricular Dysfunction After Acute MI
- Lead sponsor
- Quantum Genomics SA
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- June 4, 2019
- Completion date
- July 8, 2021
- Enrollment
- 295 (actual)
- Sites
- 7
Conditions
As the registry lists them; a condition with its own page is linked.